However, we also reported the enrichment of ESR1 mutation with long-term neoadjuvant AI in primary breast cancer using a real-world cohort of patients treated in the Royal Marsden Hospital (RMH; London, United Kingdom; ref. 16). The gene discussed is ESR1; the disease is breast cancer.